Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine
Moderna (NASDAQ:MRNA) has received marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for mRESVIA, its RSV vaccine for adults 60 years and older. This marks Moderna's second approved product in the UK.
The vaccine, designed to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV), will be manufactured at the Moderna Innovation and Technology Centre in Oxfordshire. RSV significantly impacts UK elderly adults, causing 175,000 GP appointments, 14,000 hospitalizations, and 8,000 deaths annually in those 65 and older.
The approval is based on the Phase 3 ConquerRSV trial, which involved approximately 37,000 adults aged 60+ across 22 countries. No serious safety concerns were identified during the trial.
Moderna (NASDAQ:MRNA) ha ricevuto l'autorizzazione alla commercializzazione dall'Agenzia Regolatoria dei Medicinali e dei Prodotti Sanitari del Regno Unito (MHRA) per mRESVIA, il suo vaccino RSV per adulti di 60 anni e oltre. Questo segna il secondo prodotto approvato da Moderna nel Regno Unito.
Il vaccino, progettato per prevenire le malattie delle vie respiratorie inferiori causate dal virus respiratorio sinciziale (RSV), sarà prodotto presso il Centro Innovazione e Tecnologia di Moderna in Oxfordshire. L'RSV ha un impatto significativo sugli adulti anziani nel Regno Unito, causando 175.000 appuntamenti dal medico di base, 14.000 ricoveri e 8.000 decessi annuali tra coloro che hanno 65 anni e più.
L'approvazione si basa sul trial di Fase 3 ConquerRSV, che ha coinvolto circa 37.000 adulti di età superiore ai 60 anni in 22 paesi. Durante il trial non sono state identificate preoccupazioni significative per la sicurezza.
Moderna (NASDAQ:MRNA) ha recibido la autorización de comercialización de la Agencia Reguladora de Medicamentos y Productos Sanitarios del Reino Unido (MHRA) para mRESVIA, su vacuna contra el RSV para adultos de 60 años o más. Esto marca el segundo producto aprobado de Moderna en el Reino Unido.
La vacuna, diseñada para prevenir enfermedades del tracto respiratorio inferior causadas por el virus sincitial respiratorio (RSV), se fabricará en el Centro de Innovación y Tecnología de Moderna en Oxfordshire. El RSV impacta significativamente a los adultos mayores en el Reino Unido, causando 175,000 citas con el médico, 14,000 hospitalizaciones y 8,000 muertes anuales en personas de 65 años o más.
La aprobación se basa en el ensayo de Fase 3 ConquerRSV, que involucró aproximadamente a 37,000 adultos de 60 años o más en 22 países. No se identificaron preocupaciones graves de seguridad durante el ensayo.
모더나 (NASDAQ:MRNA)는 영국 의약품 및 건강 관리 제품 규제 기관(MHRA)으로부터 60세 이상의 성인을 위한 RSV 백신인 mRESVIA에 대한 마케팅 승인을 받았습니다. 이는 모더나가 영국에서 승인받은 두 번째 제품입니다.
이 백신은 호흡기 세포 융합 바이러스(RSV)로 인한 하부 호흡기 질환을 예방하기 위해 설계되었으며, 옥스포드셔에 있는 모더나 혁신 및 기술 센터에서 제조될 예정입니다. RSV는 영국의 노인에게 심각한 영향을 미치며, 매년 65세 이상에서 175,000회의 GP 예약, 14,000회의 입원, 8,000명의 사망을 초래합니다.
이번 승인은 22개국에서 60세 이상의 약 37,000명을 대상으로 한 3상 ConquerRSV 시험에 기반하고 있으며, 시험 중 심각한 안전성 문제는 발견되지 않았습니다.
Moderna (NASDAQ:MRNA) a reçu l'autorisation de mise sur le marché de l'Agence des médicaments et des produits de santé du Royaume-Uni (MHRA) pour mRESVIA, son vaccin contre le RSV destiné aux adultes de 60 ans et plus. Cela marque le deuxième produit approuvé par Moderna au Royaume-Uni.
Le vaccin, conçu pour prévenir les maladies des voies respiratoires inférieures causées par le virus respiratoire syncytial (RSV), sera fabriqué au Centre d'Innovation et de Technologie de Moderna en Oxfordshire. Le RSV a un impact significatif sur les adultes âgés au Royaume-Uni, entraînant 175 000 rendez-vous chez le médecin, 14 000 hospitalisations et 8 000 décès chaque année chez les personnes de 65 ans et plus.
L'approbation est basée sur l'
Moderna (NASDAQ:MRNA) hat die Marktzulassung von der britischen Arzneimittel- und Gesundheitsbehörde (MHRA) für mRESVIA, seinen RSV-Impfstoff für Erwachsene ab 60 Jahren, erhalten. Dies ist das zweite genehmigte Produkt von Moderna im Vereinigten Königreich.
Der Impfstoff, der zur Vorbeugung von Erkrankungen der unteren Atemwege durch das respiratorische Synzytialvirus (RSV) entwickelt wurde, wird im Moderna Innovations- und Technologiezentrum in Oxfordshire hergestellt. RSV hat erhebliche Auswirkungen auf ältere Erwachsene im Vereinigten Königreich und verursacht jährlich 175.000 Arztbesuche, 14.000 Krankenhausaufenthalte und 8.000 Todesfälle bei Personen ab 65 Jahren.
Die Genehmigung basiert auf der Phase-3-Studie ConquerRSV, an der etwa 37.000 Erwachsene ab 60 Jahren aus 22 Ländern teilnahmen. Während der Studie wurden keine ernsthaften Sicherheitsbedenken festgestellt.
- Second product approval in UK market expands revenue potential
- Large addressable market: 175,000 annual GP visits and 14,000 hospitalizations in UK
- Manufacturing facility in Oxfordshire ensures local production capability
- Successful Phase 3 trial with 37,000 participants showing positive safety profile
- Manufacturing facility not yet operational, pending later 2025 launch
- Faces competition in established RSV vaccine market
mRESVIA® is Moderna's second approved product in the UK
CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.
"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna. "Our RSV vaccine will be manufactured at the Moderna Innovation and Technology Centre in Oxfordshire, which will be fully operational later this year."
RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia. In the UK, RSV has an impact on elderly adults and is responsible for 175,000 GP appointments, 14,000 hospitalizations, and 8,000 deaths in adults 65 years of age and older per year.[i]
"Given the serious consequences of RSV for older people, which can lead to hospitalization and severe outcomes, we are delighted that the MHRA has authorized our RSV vaccine," said Darius Hughes, UK General Manager of Moderna. "With the MHRA decision, mRESVIA becomes Moderna's second approved product in the UK, further demonstrating the role of mRNA vaccines in helping to protect the public from respiratory diseases."
The approval is based on positive data from the Phase 3 clinical trial ConquerRSV, a randomized, placebo-controlled, observer-blind, case-driven clinical study conducted in approximately 37,000 adults aged 60 years or older in 22 countries. No serious safety concerns were identified in the Phase 3 trial.
About mRNA-1345 (Respiratory Syncytial Virus Vaccine)
mRNA-1345 is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells. The prefusion conformation of the F protein is a significant target of potent neutralizing antibodies and is highly conserved across both RSV-A and RSV-B subtypes.
To date, Moderna has received marketing authorizations for its RSV vaccine in the United States, the European Union, Canada, Qatar, the United Arab Emirates, and Taiwan and has submitted regulatory applications in other markets worldwide.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the vaccine efficacy and safety of mRNA-1345; the potential for mRESVIA to reduce disease burden from RSV; Moderna's expectation that the MITC will be fully operational later this year; and Moderna's regulatory applications worldwide. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
International Media:
Luke Mircea-Willats
Senior Director, International Communications
Luke.mirceawillats@modernatx.com
UK Media:
Emma Gilgunn-Jones
Director, UK Communications
Emma.gilgunn-jones@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
1. | Fleming, D.M., Taylor, R.J., Lustig, R.L. et al. Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect Dis 15, 443 (2015). https://doi.org/10.1186/s12879-015-1218-z |
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the efficacy data for Moderna's RSV vaccine mRESVIA (MRNA)?
Where will Moderna (MRNA) manufacture its newly approved RSV vaccine?
What is the target population for Moderna's RSV vaccine mRESVIA in the UK?
What is the impact of RSV on the UK healthcare system that Moderna's vaccine (MRNA) aims to address?
